Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare. - Roth JA; Kratochvil D; Dorman S; Bernauer M (Journal of medical economics, 2025)